Project cooperationUpdated on 2 February 2026

Nanomaterials for biomedical applications

Associate Professor at Loughborough University

Loughborough, United Kingdom

About

My research is on:

Nanofibrous systems that enhance cell proliferation and cell encapsulation
Dressings incorporating antimicrobial, anti‑inflammatory, or essential‑oil‑based bioactive agents
Stimuli‑responsive fibres designed for controlled drug release
Nanocomposites with tunable surface and mechanical properties, to achieve properties such as improved mechanical strength, controlled surface wettability, tailored degradation behaviour.

Topic

DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

Type

Partner seeks Consortium/Coordinator

Similar opportunities

Project cooperation
Advanced Nanoparticle Platforms for Targeted Therapeutics and Gene Delivery
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
Paola Astolfi
Associate professor at Università Politecnica delle Marche
Ancona, Italy
Project cooperation
Looking for Consortium
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Oscar Castano
Tenured Associate Professor at Universitat de Barcelona
Barcelona, Spain
Project cooperation
Nanolive – Cooperation Profile
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Yann Cotte
CEO at Nanolive
Tolochenaz, Switzerland